Consensus Recommendations for the Diagnosis, Biomarker Testing, and Clinical Management of Advanced or Metastatic Non-small Cell Lung Cancer With Mesenchymal-Epithelial Transition Exon 14 Skipping Mutations in the Middle East, Africa, and Russia

Mesenchymal-epithelial transition exon 14 (METex14) skipping mutations occur in about 3%-4% of patients with non-small cell lung cancer (NSCLC). This is an aggressive subtype associated with poor prognosis. METex14 skipping is a potentially targetable mutation. Targeted therapy is a promising treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahrous, Mervat, Omar Jebriel, Abdalla, Allehebi, Ahmed, Shafik, Amr, El Karak, Fadi, Venturini, Filippo, Alhusaini, Hamed, Meergans, Matthias, Ali Nahit Sendur, Mehmet, Ouda, Mohamed, Al-Nassar, Muath, Kilickap, Saadettin, Al Turki, Saeed, Al-Fayea, Turki, Abdel Kader, Yasser
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365828/
https://www.ncbi.nlm.nih.gov/pubmed/37492039
http://dx.doi.org/10.7759/cureus.41992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365828/
https://www.ncbi.nlm.nih.gov/pubmed/37492039
http://dx.doi.org/10.7759/cureus.41992

Ejemplares similares